AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20465650 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 20
Study 18703472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (1.25 mg once daily)
Number of subjects: 4538
Study 18703472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4538
Study 15851913 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected women
Number of subjects: 100
Study 15851913 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy female subjects)
Number of subjects: 100
Study 12576957 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+GLA
Number of subjects: 67
Study 12576957 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 67
Study 9804518 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL apheresis
Number of subjects: 44
Study 9804518 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 44
Study 9804518 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 44
Study 9804518 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 44
Study 7879457 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapidil
Number of subjects: 160
Study 7879457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 2234856 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin surface-modified (HSM) lenses
Number of subjects: 53
Study 2234856 — intervention group
Group type: COMPARATOR
Intervention: Regular PMMA lenses
Number of subjects: 53
Study 197800 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (single oral dose)
Number of subjects: 0
Study 197800 — intervention group
Group type: EXPERIMENTAL
Intervention: Desoxycorticosterone (single oral dose)
Number of subjects: 0
Study 197800 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH (two i.v. injections of 60 IU each, at a 6-hour interval)
Number of subjects: 0
Study 30068252 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker group
Number of subjects: 98
Study 30068252 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging group
Number of subjects: 98
Study 30068252 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity tracker + text messaging group
Number of subjects: 98
Study 30141342 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotus valve system (Boston Scientific, MA, USA)
Number of subjects: 0
Study 30141342 — intervention group
Group type: COMPARATOR
Intervention: Self-expanding valve
Number of subjects: 0
Study 28923989 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin plus ezetimibe
Number of subjects: 18131
Study 26247327 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist-aided exposure treatment for 3 months
Number of subjects: 70
Study 26247327 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 70
Study 24093349 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual causal model (dual-mode) presentation
Number of subjects: 190
Study 24093349 — intervention group
Group type: COMPARATOR
Intervention: Auditory-only presentation
Number of subjects: 190
Study 21178600 — intervention group
Group type: EXPERIMENTAL
Intervention: New back school
Number of subjects: 360
Study 21178600 — intervention group
Group type: COMPARATOR
Intervention: Traditional back school (usual care)
Number of subjects: 360
Study 18316661 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention to reduce television viewing and computer use by 50%
Number of subjects: 70
Study 18316661 — intervention group
Group type: COMPARATOR
Intervention: Monitoring control group (no reduction in television viewing or computer use)
Number of subjects: 70
Study 16584341 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing followed by local application of doxycycline (SRP-D)
Number of subjects: 48
Study 16584341 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 48
Study 14535875 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCAT (ranitidine bismuth citrate 400 mg b.d. plus amoxicillin 1 g b.d. and tinidazole 500 mg b.d.)
Number of subjects: 180
Study 14535875 — intervention group
Group type: EXPERIMENTAL
Intervention: PAL (pantoprazole 40 mg b.d. plus amoxicillin 1 g b.d. and levofloxacin 500 mg/day)
Number of subjects: 180
Study 14535875 — intervention group
Group type: EXPERIMENTAL
Intervention: PBTM (pantoprazole 40 mg b.d., bismuth citrate 240 mg b.d., tetracycline 500 mg q.d.s. and metronidazole 500 mg b.d.)
Number of subjects: 180
Study 14535875 — intervention group
Group type: EXPERIMENTAL
Intervention: PBTM
Number of subjects: 180
Study 11899411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissection/snare technique
Number of subjects: 50
Study 11899411 — intervention group
Group type: COMPARATOR
Intervention: Suction-cautery technique
Number of subjects: 50
Study 9771208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical etidronate and calcitriol (E + C)
Number of subjects: 47
Study 9771208 — intervention group
Group type: COMPARATOR
Intervention: Cyclical etidronate (E)
Number of subjects: 47
Study 8116547 — intervention group
Group type: EXPERIMENTAL
Intervention: Monounsaturated rapeseed oil diet
Number of subjects: 95
Study 8116547 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil diet
Number of subjects: 95
Study 3294020 — intervention group
Group type: EXPERIMENTAL
Intervention: bepridil 900 mg followed by 300 mg daily for 11 days
Number of subjects: 37
Study 1603890 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam 0.25 mg (active drug)
Number of subjects: 21
Study 1603890 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 21
Study 373778 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretolytic drugs
Number of subjects: 0
Study 373778 — intervention group
Group type: EXPERIMENTAL
Intervention: Respirophonography
Number of subjects: 0
Study 31264286 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (instructed to increase stride-rate by 10% using a watch and foot pod for feedback)
Number of subjects: 38
Study 31264286 — intervention group
Group type: COMPARATOR
Intervention: Control group (instructed to continue normal running)
Number of subjects: 38
Study 28350328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (50,000 IU of oral VitD3 once weekly for 8 weeks)
Number of subjects: 68
Study 27701025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse led telephone supportive care programme
Number of subjects: 0
Study 27701025 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 0
Study 24929429 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop control (CLC)
Number of subjects: 20
Study 24929429 — intervention group
Group type: COMPARATOR
Intervention: Open-loop (OL) sensor-augmented insulin pump therapy
Number of subjects: 20
Study 21941187 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol sedation
Number of subjects: 214
Study 21941187 — intervention group
Group type: COMPARATOR
Intervention: Standard sedation with benzodiazepines and opioids
Number of subjects: 214
Study 19441980 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B 0.7 mg/kg plus fluconazole 800 mg
Number of subjects: 143
Study 19441980 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B 0.7 mg/kg plus fluconazole 400 mg
Number of subjects: 143
Study 19441980 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B 0.7 mg/kg (standard therapy)
Number of subjects: 143
Study 17690547 — intervention group
Group type: EXPERIMENTAL
Intervention: rt‐PA
Number of subjects: 615
Study 17690547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 615
Study 15161435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta®) plus cisplatin
Number of subjects: 0
Study 15161435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta®)
Number of subjects: 0
Study 15161435 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Alimta®) with vitamin B12 and folate supplementation
Number of subjects: 0
Study 11943793 — intervention group
Group type: EXPERIMENTAL
Intervention: New South Wales mammographic screening programme
Number of subjects: 0
Study 11943793 — intervention group
Group type: COMPARATOR
Intervention: Randomised trials of screening
Number of subjects: 0
Study 11943793 — intervention group
Group type: COMPARATOR
Intervention: Service studies
Number of subjects: 0
Study 9827927 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD (vincristine, doxorubicin, dexamethasone)
Number of subjects: 263
Study 9827927 — intervention group
Group type: EXPERIMENTAL
Intervention: VMBCP (vincristine, BCNU, cyclophosphamide, melphalan and prednisone)
Number of subjects: 263
Study 9827927 — intervention group
Group type: COMPARATOR
Intervention: VAD
Number of subjects: 263
Study 9827927 — intervention group
Group type: COMPARATOR
Intervention: VMBCP
Number of subjects: 263
Study 9827927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both VAD and VMBCP
Number of subjects: 263
Study 9827927 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky index > 60 and albuminaemia > or = 34 g/l
Number of subjects: 263
Study 9827927 — intervention group
Group type: EXPERIMENTAL
Intervention: Karnofsky index < or = 60 and albuminaemia < 34 g/l
Number of subjects: 263
Study 8015506 — intervention group
Group type: EXPERIMENTAL
Intervention: Klimaxil (17 beta‐estradiol 2 mg and medroxy‐progesterone acetate 5 mg)
Number of subjects: 12
Study 8015506 — intervention group
Group type: EXPERIMENTAL
Intervention: Divina (17 beta‐estradiol valerate 2 mg and medroxyprogesterone acetate 10 mg)
Number of subjects: 12
Study 8015506 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisequence (17 beta‐estradiol 2 mg in the first phase) and Provera (medroxyprogesterone acetate 5 mg)
Number of subjects: 12
Study 8015506 — intervention group
Group type: EXPERIMENTAL
Intervention: All drugs
Number of subjects: 12
Study 2816769 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial color Doppler echocardiography
Number of subjects: 22
Study 2816769 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal color Doppler echocardiography
Number of subjects: 22
Study 2816769 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal color flow mapping
Number of subjects: 22
Study 2816769 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicardial color flow mapping
Number of subjects: 22
Study 2110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-nasal beclomethasone dipropionate (400 mug/day)
Number of subjects: 18
Study 2110 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 18
Study 31237318 — intervention group
Group type: EXPERIMENTAL
Intervention: Tesamorelin
Number of subjects: 341
Study 31237318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 341
Study 28377342 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB)
Number of subjects: 46
Study 28377342 — intervention group
Group type: COMPARATOR
Intervention: Common balloon (CB)
Number of subjects: 46
Study 28377342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 25311593 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 12 weeks (60 mg once daily) + peginterferon alfa-2a + ribavirin
Number of subjects: 151
Study 25311593 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclatasvir 16 weeks (60 mg once daily) + peginterferon alfa-2a + ribavirin
Number of subjects: 151
Study 25311593 — intervention group
Group type: COMPARATOR
Intervention: Placebo + peginterferon alfa-2a + ribavirin
Number of subjects: 151
Study 24054755 — intervention group
Group type: EXPERIMENTAL
Intervention: Transatrial-transpulmonary approach (Group A)
Number of subjects: 106
Study 24054755 — intervention group
Group type: COMPARATOR
Intervention: Transventricular approach (Group B)
Number of subjects: 106
Study 21632064 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's Wort (810 mg/day)
Number of subjects: 0
Study 21632064 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day)
Number of subjects: 0
Study 21632064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18838245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel Node (SN) biopsy only
Number of subjects: 150
Study 18838245 — intervention group
Group type: COMPARATOR
Intervention: Axillary Lymph Node Dissection (ALND)
Number of subjects: 150
Study 16876451 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice and 0.5 g MCT per kg lean body mass
Number of subjects: 9
Study 16876451 — intervention group
Group type: COMPARATOR
Intervention: Orange juice alone
Number of subjects: 9
Study 15702625 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0
Study 15702625 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (CCB)
Number of subjects: 0
Study 15702625 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors, CCBs, and conventional treatment (diuretics/beta-blockers)
Number of subjects: 0
Study 15702625 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 0
Study 15702625 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering treatments
Number of subjects: 0
Study 15702625 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimens based on different drug classes
Number of subjects: 0
Study 10687323 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (OCT) 0.3 mg/day for 3 days
Number of subjects: 17
Study 10687323 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine butylbromide (SB) 60 mg/day for 3 days
Number of subjects: 17
Study 10687323 — intervention group
Group type: COMPARATOR
Intervention: Parenteral hydration
Number of subjects: 17
Study 10687323 — intervention group
Group type: COMPARATOR
Intervention: Less parenteral hydration
Number of subjects: 17
Study 10687323 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain relief treatment
Number of subjects: 17
Study 9352972 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of knee extensor endurance training
Number of subjects: 16
Study 1363053 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine (high concentration, 5 mg/ml; low concentration, 2.5 mg/ml) with volumes of 15-20 ml (high) or 5-10 ml (low) injected at C6 or C7
Number of subjects: 30
Study 1363053 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection toward C7 instead of C6
Number of subjects: 30
Study 1363053 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration of bupivacaine instead of low concentration
Number of subjects: 30
Study 1363053 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of bupivacaine
Number of subjects: 30
Study 1363053 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-block skin temperature
Number of subjects: 30
Study 3898351 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg twice daily)
Number of subjects: 55
Study 3898351 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 55
Study 30878612 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping treatment
Number of subjects: 67
Study 30878612 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzodiazepine treatment
Number of subjects: 67
Study 30878612 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 67
Study 29239893 — intervention group
Group type: EXPERIMENTAL
Intervention: dolutegravir with rilpivirine
Number of subjects: 81
Study 29239893 — intervention group
Group type: COMPARATOR
Intervention: current ART
Number of subjects: 81
Study 28145966 — intervention group
Group type: COMPARATOR
Intervention: 0 cm H2O PEEP
Number of subjects: 105
Study 28145966 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 cm H2O PEEP
Number of subjects: 105
Study 28145966 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm H2O PEEP
Number of subjects: 105
Study 26637993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular seven‐faceted screening examinations including low‐dose non‐contrast CT scan, brachial and ankle blood pressure index, telemetric assessment of heart rhythm, cholesterol and plasma glucose measurement.
Number of subjects: 45000
Study 26637993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening).
Number of subjects: 45000
Study 23924453 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lamina replantation
Number of subjects: 124
Study 23924453 — intervention group
Group type: COMPARATOR
Intervention: Traditional laminectomy replantation
Number of subjects: 124
Study 23924453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Modified and Traditional)
Number of subjects: 124
Study 20878375 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block (SCPB) with 20 mL of a 1:1 mixture of 0.5% bupivacaine and 2% lidocaine
Number of subjects: 30
Study 20878375 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg·kg⁻¹ iv after dural closure
Number of subjects: 30
Study 20878375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 18420853 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol plus ondansetron
Number of subjects: 268
Study 18420853 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron alone (saline control)
Number of subjects: 268
Study 16647354 — intervention group
Group type: EXPERIMENTAL
Intervention: Early drain removal on postoperative day 2
Number of subjects: 27
Study 16647354 — intervention group
Group type: COMPARATOR
Intervention: Standard drain removal (< 30 mL drainage in 24 hours or postoperative day 14)
Number of subjects: 27
Study 12952111 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at study visits
Number of subjects: 1041
Study 12952111 — intervention group
Group type: EXPERIMENTAL
Intervention: Study dropout
Number of subjects: 1041
Study 12952111 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with missed visits
Number of subjects: 1041
Study 12952111 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics of study dropouts
Number of subjects: 1041
Study 12952111 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance patterns
Number of subjects: 1041
Study 10372699 — intervention group
Group type: COMPARATOR
Intervention: GnRHa treatment only (Group A)
Number of subjects: 40
Study 10372699 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa for 12 months followed by calcium supplementation (Group B)
Number of subjects: 40
Study 10372699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GnRHa and calcium from the beginning (Group C)
Number of subjects: 40
Study 8720819 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based medical teaching (CBMT)
Number of subjects: 103
Study 8720819 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CBMT)
Number of subjects: 103
Study 8720819 — intervention group
Group type: COMPARATOR
Intervention: Control test (not related to CBMT)
Number of subjects: 103
Study 1679252 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative somatic treatments for schizophrenia
Number of subjects: 0
Study 7237025 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (1 deamino‐8‐D‐arginine vasopressin) at a dose of 1 microgram
Number of subjects: 2
Study 7237025 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (1 deamino‐8‐D‐arginine vasopressin) at a minimum effective dose of 2 ng/kg
Number of subjects: 2
Study 7237025 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (1 deamino‐8‐D‐arginine vasopressin)
Number of subjects: 2
Study 30784208 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04895162 (300 mg twice daily for 2 weeks)
Number of subjects: 8
Study 30784208 — intervention group
Group type: EXPERIMENTAL
Intervention: PF‐04895162
Number of subjects: 8
Study 28106903 — intervention group
Group type: EXPERIMENTAL
Intervention: Rd continuous (lenalidomide plus low-dose dexamethasone)
Number of subjects: 114
Study 28106903 — intervention group
Group type: COMPARATOR
Intervention: MPT (melphalan, prednisone, thalidomide)
Number of subjects: 114
Study 28106903 — intervention group
Group type: COMPARATOR
Intervention: Rd18 (lenalidomide plus low-dose dexamethasone for 18 cycles)
Number of subjects: 114
Study 28106903 — intervention group
Group type: EXPERIMENTAL
Intervention: Rd continuous
Number of subjects: 114
Study 25534959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevasic plus usual care
Number of subjects: 99
Study 25534959 — intervention group
Group type: EXPERIMENTAL
Intervention: Music plus usual care
Number of subjects: 99
Study 25534959 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 99
Study 24297841 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg racemic ketamine (Keta‐Race)
Number of subjects: 28
Study 24297841 — intervention group
Group type: COMPARATOR
Intervention: 9 mg/kg S‐ketamine (S‐Keta)
Number of subjects: 28
Study 21272715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory stimuli applied to the plantar region
Number of subjects: 30
Study 21272715 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 30
Study 19616440 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinued 5 days prior to surgery (group 1)
Number of subjects: 130
Study 19616440 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinued 3 days prior to surgery (group 2)
Number of subjects: 130
Study 19616440 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel discontinued on the day of surgery (group 3)
Number of subjects: 130
Study 16513614 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical dynamic CT (HDCT)
Number of subjects: 119
Study 16513614 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated PET/CT
Number of subjects: 119
Study 12607287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment for 12 weeks
Number of subjects: 18
Study 12607287 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment for 6 weeks
Number of subjects: 18
Study 10691121 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group (serum AED concentration adjusted to target range)
Number of subjects: 180
Study 10691121 — intervention group
Group type: COMPARATOR
Intervention: Control group (dosage adjusted on clinical grounds)
Number of subjects: 180
Study 10691121 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring group
Number of subjects: 180
Study 10691121 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180